Click here for details.
The head-to-head, Comparative Cost-Effectiveness of one medical device, pharmaceutical, or technology vs. its key competitors is perhaps the most critical data in health care today.
CAVA’s Cost-Effectiveness analytics — which determine the total episode-of-care cost of a product or health care intervention to one or more alternatives — enables:
However, Comparative Cost-Effectiveness (CCE) remains one of the greatest business intelligence data gaps in health care today…until now.
CAVA is the leader in online Comparative Cost-Effectiveness analytics and services. We help our Hospital / IDN, Device and Pharmaceutical industry, and Payer clients leverage CCE analytics for their most demanding economic and clinical purchasing, usage, commercialization, and coverage challenges.
CAVA’s clients include Hospitals and Integrated Delivery Networks; the Medical-Surgical Device and Pharmaceutical Industry in North America, Europe and around the world; and Payers. We design and deliver insightful, proprietary, online Cost-Effectiveness analytics and world-class Cost-Effectiveness programs that are rapidly changing the way health care determines comparative product value. To learn more about how CAVA can make a powerful, immediate contribution to you organization, please contact our senior management team today for a 30-minute live demonstration of our solutions.
Customized online CCE analytics that demonstrate total episode-of-care costs in side-by-side product comparisons using our proprietary, interactive platform.Learn More
CE analytics and predictive modeling solutions that allow medical-surgical clients to proactively and transparently demonstrate the comparative value of their technology.Learn More
Customized online CCE models and data analytics programs to demonstrate objective clinical and economic advantages of pharmaceutical products vs. key comparators.Learn More
CAVA Robotics offers hospitals proprietary, industry-leading predictive analytics to assess the economic, clinical, and operational cost-effectiveness of its da Vinci robotics program.Learn More